FXYD5 is a marker for poor prognosis and a potential driver for metastasis in ovarian carcinomas

Cancer Informatics

Volumn 14, Issue , 2015, Pages 113-119

  Raman, Pichai ^a,b,c   Purwin, Timothy ^a   Pestell, Richard ^d   Tozeren, Aydin ^a  

^a DREXEL UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Fara Diagnostics   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Dysadherin; FXYD5; Ovarian cancer; Survival; TCGA

Indexed keywords

DYSADHERIN; PROTEIN ANTIBODY; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; COPY NUMBER AMPLIFICATION; COPY NUMBER VARIATION; FXYD5 GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME; HUMAN; METASTASIS; OVARY CARCINOMA; SURVIVAL; TISSUE MICROARRAY; VALIDATION PROCESS;

EID: 84949951649     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S30565     Document Type: Article

References (36)

1. Baldwin L, Ware R, Huang B, et al. Ten-year relative survival for epithelial ovarian cancer. Gynecol Oncol. 2011;120:S34–5.
2. McCluggage W. Morphological subtypes of ovarian carcinoma. Pathology. 2011;43(5):420–32.
3. Bolton K, Ganda C, Berchuck A, Pharaoh P, Gayther S. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC). J Intern Med. 2012;271(4):366–78.
4. Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Genetic changes in nonepithelial ovarian cancer. Expert Rev Anticancer Ther. 2013;13(7):871–82.
5. Braem M, Schouten L, Peeters P, den Brandt P, Onland-Moret N. Genetic susceptibility to sporadic ovarian cancer: a systematic review. Biochim Biophys Acta. 2011;1816(2):132–46.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
7. Sung C, Song I, Sohn I. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19. Gynecol Oncol. 2014;132(2):343–50.
8. Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci U S A. 2001;99(1):365–70.
9. Miller T, Davis P. S163 is critical for FXYD5 modulation of wound healing in airway epithelial cells. Wound Repair Regen. 2008;16(6):791–9.
10. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for functional genomics data sets–10 years on. Nucleic Acids Res. 2010;39(Database):D1005–10.
11. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2012;41(D1):D991–5.
12. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7.
13. Ponten F, Jirström K, Uhlen M. The human protein Atlas-a tool for pathology. J Pathol. 2008;216(4):387–93.
14. Lee YK, Lee SY, Park JR, et al. Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation. Cancer Sci. 2012;103(7):1280–9.
15. Schroeder M, Rubio-Perez C, Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action. Bioinformatics. 2014;30(17):i549-i555. doi:10.1093/bioinformatics/btu467.
16. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650.
17. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3 K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.
18. Colamaio M, Calì G, Sarnataro D, et al. Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (dysadherin) gene. J Clin Endocrinol Metab. 2012;97(11):E2168–78.
19. Schüler Y, Lee-Thedieck C, Geiger K, et al. Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells. Int J Cancer. 2011;130(2):288–99.
20. Subramaniam M, Navarro S, Llombart-Bosch A. Immunohistochemical study of correlation between histologic subtype and expression of epithelial-mesenchymal transition-related proteins in synovial sarcomas. Arch Pathol Lab Med. 2011;135(8):1001–9.
21. Park JR, Kim RJ, Lee YK, et al. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J Hepatol. 2011;54(1):122–31.
22. Maehata Y, Hirahashi M, Aishima S, et al. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion. Hum Pathol. 2011;42(4):558–67.
23. Liang J, Zheng H, Xiao H, Li N, Cheng C, Wang H. Dysadherin expression in gastrointestinal stromal tumors (GISTs). Pathol Res Pract. 2009;205(7):445–50.
24. Ochiai H, Nakanishi Y, Fukasawa Y, et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology. 2008;75(1–2):32–41.
25. Batistatou A, Charalabopoulos AK, Scopa CD, et al. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch. 2006;448(6):763–7.
26. Kyzas PA, Stefanou D, Batistatou A, et al. Dysadherin expression in head and neck squamous cell carcinoma. Am J Surg Pathol. 2006;30(2):185–93.
27. Batistatou A, Scopa CD, Ravazoula P, et al. Involvement of dysadherin and E-cadherin in the development of testicular tumours. Br J Cancer. 2005;93(12):1382–7.
28. Tamura M, Ohta Y, Tsunezuka Y, et al. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130(3):740–5.
29. Nishizawa A, Nakanishi Y, Yoshimura K, et al. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma. Cancer. 2005;103(8):1693–700.
30. Wu D, Qiao Y, Kristensen GB, et al. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res. 2004;10(4):212–8.
31. Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol. 2010;10(4):212–8.
32. Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Applied Immunohistochemistry and Molecular Morphology. 2004;12(4):323–8.
33. Shimada Y, Hashimoto Y, Kan T, et al. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology. 2004;67(1):73–80.
34. Shimada Y. Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res. 2004;10(8):2818–23.
35. Sato H, Ino Y, Miura A, et al. Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(9):4407–12.
36. Shimamura T. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol. 2003;21(4):659–67.